Cure8 research brief
The study maps cell-level programs in ileum and colon that associate with failure to respond to biologic therapies, suggesting specific cellular markers and niches that could help explain treatment resistance and guide future biomarker-driven approaches.
Researchers studying IBD pathogenesis or biomarkers, translational clinicians interested in treatment resistance, and biologic drug developers.
This is a preprint reporting new single-cell and spatial data that define cellular ecosystems in ileal and colonic mucosa and associate specific cell programs with lack of response to biologics.
The authors highlight TNF-expressing macrophages, epithelial markers (BPIFB1), and FAP+ stromal cells as part of a non-responder signature, and validate co-expression differences in prior datasets.
The work offers potential biomarker candidates and a framework for stratifying treatment resistance, but it does not by itself establish clinically actionable tests or therapies. Further validation and peer review will be needed before findings change patient care.
Preprint on bioRxiv; not yet peer reviewed. Results are based on single-cell and spatial transcriptomics and need independent replication and clinical validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study points to CD226 (DNAM-1) being linked to inflammatory and interferon-driven programs in specific intestinal immune cells in Crohn's disease, which may be relevant to understanding disease mechanisms or...
Spatial, high-plex mapping of immune cells in the colon helps reveal how immune cells and stromal cells are organized in IBD versus normal tissue. That information could help researchers identify new biomarkers or...
This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...
